Home > Resources > Whitepapers > Covid-19 Vaccine Distribution System

MedTech

Covid-19 Vaccine Distribution System

April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits.

Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet.

To read more, please download this free white paper.

Spotlight

Nawah Healthcare

Nawah is a leader in healthcare and medical technology, specializing in providing patient care expertise and the latest medical technologies in the Kingdom of Saudi Arabia (KSA). Nawah is dedicated to catalysing improvement in KSA’s healthcare sector by offering globally renowned products and technologies to healthcare providers, and making a genuine difference to the quality of treatment patients receive. An ISO 9001:2008 certified company, Nawah is a subsidiary of the well-known Nazer Group of Companies, and the newest iteration of recognized healthcare and medical services provider AMCO.

OTHER WHITEPAPERS

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

Internal Co-ordination Group for Biotechnology

whitePaper | October 19, 2022

The Organisation for Economic Co-operation and Development and its member countries have been addressing issues related to biotechnology since 1982.

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Bispecific Antibodies - CMC Considerations

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

Biosimilars in the United States 2023–2027

whitePaper | January 31, 2023

The first biosimilar approved under the abbreviated pathway established by the Biologics Price Competition and Innovation Act launched in the U.S. in 2015.

Connecting materials sciences with fungal biology: a sea of possibilities

whitePaper | March 1, 2022

The Special Issue “Connecting materials science with fungal biology” celebrates recent breakthroughs in the fabrication of fungal-based materials, all of which have been made possible by the interdisciplinary and transdisciplinary collaboration of fungal biologists and biotechnologists with artists, designers, materials scientists, and architects